{"count": 6, "results": [{"_id": "32902818", "pmid": 32902818, "pmcid": "PMC7479299", "title": "A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin", "journal": "Geroscience", "authors": ["Justice JN", "Gubbi S", "Kulkarni AS", "Bartley JM", "Kuchel GA", "Barzilai N"], "date": "2021-06-01T00:00:00Z", "doi": "10.1007/s11357-020-00261-6", "meta_date_publication": "2021 Jun", "meta_volume": "43", "meta_issue": "3", "meta_pages": "1093-1112", "score": 50261.57, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ acts through a few widely accepted cellular and molecular mechanisms that are highly interdependent and implicated @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@'s downstream effects on immune response, @DISEASE_Chronic_Disease @DISEASE_MESH:D002908 @@@chronic diseases@@@, and @<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@geriatric syndromes@@@ (Table 1). ", "citations": {"NLM": "Justice JN, Gubbi S, Kulkarni AS, Bartley JM, Kuchel GA, Barzilai N. A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin Geroscience. 2021 Jun;43(3):1093-1112. PMID: 32902818", "BibTeX": "@article{32902818, title={A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin}, author={Justice JN and Gubbi S and Kulkarni AS and Bartley JM and Kuchel GA and Barzilai N}, journal={Geroscience}, volume={43}, number={3}, pages={1093-1112}}"}}, {"_id": "35321338", "pmid": 35321338, "pmcid": "PMC8935075", "title": "Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort", "journal": "Front Endocrinol (Lausanne)", "authors": ["Wong CKH", "Lui DTW", "Lui AYC", "Low MCH", "Kwok ACY", "Lau KTK", "Au ICH", "Xiong X", "Chung MSH", "Lau EHY", "Cowling BJ"], "date": "2022-03-07T00:00:00Z", "doi": "10.3389/fendo.2022.810914", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "810914", "score": 50253.016, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use was associated with lower mortality and lower odds for @<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@hyperinflammatory syndrome@@@. ", "citations": {"NLM": "Wong CKH, Lui DTW, Lui AYC, Low MCH, Kwok ACY, Lau KTK, Au ICH, Xiong X, Chung MSH, Lau EHY, Cowling BJ. Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort Front Endocrinol (Lausanne). 2022;13():810914. PMID: 35321338", "BibTeX": "@article{35321338, title={Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort}, author={Wong CKH and Lui DTW and Lui AYC and Low MCH and Kwok ACY and Lau KTK and Au ICH and Xiong X and Chung MSH and Lau EHY and Cowling BJ}, journal={Front Endocrinol (Lausanne)}, volume={13}, pages={810914}}"}}, {"_id": "38467496", "pmid": 38467496, "title": "Acupotomy combined with metformin hydrochloride tablet for type 2 diabetes mellitus and its effect on serum inflammatory factors.", "journal": "Zhongguo Zhen Jiu", "authors": ["Zhu T", "Ji L", "Gao Z", "Ren J", "Ji Y", "Miao J"], "date": "2024-03-12T00:00:00Z", "doi": "10.13703/j.0255-2930.20230705-k0002", "meta_date_publication": "2024 Mar 12", "meta_volume": "44", "meta_issue": "3", "meta_pages": "245-250", "score": 50248.777, "text_hl": "After treatment, in the acupotomy group, the FBG, HbA1c, TCM @<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@syndrome@@@ score, @CHEMICAL_Technetium @CHEMICAL_MESH:D013667 @@@TC@@@, @CHEMICAL_Thioguanine @CHEMICAL_MESH:D013866 @@@TG@@@, LDL-C, FINS, 2 h @CHEMICAL_Indium @CHEMICAL_MESH:D007204 @@@INS@@@, FC-P, 2 h C-P, dosage of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin hydrochloride@@@ tablet, DSQL score as well as the serum level of @GENE_TNF @GENE_7124 @@@TNF-alpha@@@ were lower than those in the western medication group (P<0.05). ", "citations": {"NLM": "Zhu T, Ji L, Gao Z, Ren J, Ji Y, Miao J. Acupotomy combined with metformin hydrochloride tablet for type 2 diabetes mellitus and its effect on serum inflammatory factors. Zhongguo Zhen Jiu. 2024 Mar 12;44(3):245-250. PMID: 38467496", "BibTeX": "@article{38467496, title={Acupotomy combined with metformin hydrochloride tablet for type 2 diabetes mellitus and its effect on serum inflammatory factors.}, author={Zhu T and Ji L and Gao Z and Ren J and Ji Y and Miao J}, journal={Zhongguo Zhen Jiu}, volume={44}, number={3}, pages={245-250}}"}}, {"_id": "35015744", "pmid": 35015744, "title": "Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach.", "journal": "J Acquir Immune Defic Syndr", "authors": ["Masters MC", "Landay AL", "Robbins PD", "Tchkonia T", "Kirkland JL", "Kuchel GA", "Niedernhofer LJ", "Palella FJ"], "date": "2022-02-01T00:00:00Z", "doi": "10.1097/QAI.0000000000002858", "meta_date_publication": "2022 Feb 1", "meta_volume": "89", "meta_issue": "Suppl 1", "meta_pages": "S34-S46", "score": 50235.914, "text_hl": "Therefore, drugs that target any of the pillars of @DISEASE_Aging_Premature @DISEASE_MESH:D019588 @@@aging@@@, including @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Sirolimus @CHEMICAL_MESH:D020123 @@@rapamycin@@@, and @CHEMICAL_NAD @CHEMICAL_MESH:D009243 @@@nicotinamide adenine dinucleotide@@@ precursors, may also slow the rate of onset of age-associated comorbidities and @<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@geriatric syndromes@@@ in PWH. ", "citations": {"NLM": "Masters MC, Landay AL, Robbins PD, Tchkonia T, Kirkland JL, Kuchel GA, Niedernhofer LJ, Palella FJ. Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach. J Acquir Immune Defic Syndr. 2022 Feb 1;89(Suppl 1):S34-S46. PMID: 35015744", "BibTeX": "@article{35015744, title={Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach.}, author={Masters MC and Landay AL and Robbins PD and Tchkonia T and Kirkland JL and Kuchel GA and Niedernhofer LJ and Palella FJ}, journal={J Acquir Immune Defic Syndr}, volume={89}, number={Suppl 1}, pages={S34-S46}}"}}, {"_id": "29696950", "pmid": 29696950, "title": "Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome.", "journal": "Przegl Lek", "authors": ["Kiałka M", "Gałuszka-Bednarczyk A", "Wajda A", "Czekańska P", "Zdzierak B", "Mrozińska S", "Janeczko M", "Milewicz T"], "date": "2017-01-01T00:00:00Z", "meta_date_publication": "2017", "meta_volume": "74", "meta_issue": "4", "meta_pages": "144-6", "score": 50055.69, "text_hl": "Conclusion: Our study showed thattreatment of 1500 mg @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ forabout six months among @<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@PCOS@@@ womenresults in an improvement in serumlipid profiles. ", "citations": {"NLM": "Kiałka M, Gałuszka-Bednarczyk A, Wajda A, Czekańska P, Zdzierak B, Mrozińska S, Janeczko M, Milewicz T. Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome. Przegl Lek. 2017;74(4):144-6. PMID: 29696950", "BibTeX": "@article{29696950, title={Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome.}, author={Kiałka M and Gałuszka-Bednarczyk A and Wajda A and Czekańska P and Zdzierak B and Mrozińska S and Janeczko M and Milewicz T}, journal={Przegl Lek}, volume={74}, number={4}, pages={144-6}}"}}, {"_id": "7862618", "pmid": 7862618, "title": "Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.", "journal": "Pharmacol Res", "authors": ["Sirtori CR", "Pasik C"], "date": "1994-10-01T00:00:00Z", "doi": "10.1016/1043-6618(94)80104-5", "meta_date_publication": "1994 Oct-Nov", "meta_volume": "30", "meta_issue": "3", "meta_pages": "187-228", "score": 50052.945, "text_hl": "Its mechanism of action, unknown until a few years ago, is now linked to an improved peripheral sensitivity to @GENE_INS @GENE_3630 @@@insulin@@@, through a stimulated tissue @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ uptake by a transporter linked system. Interest in @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been revived by the recent observation of a specific activity of this agent on some of the major traits of the so called '@<m>DISEASE_Syndrome</m> @DISEASE_MESH:D013577 @@@polymetabolic syndrome@@@' (or '@DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@syndrome X@@@'), characterized by: @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, @DISEASE_Hypertriglyceridemia @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and reduced fibrinolytic activity. ", "citations": {"NLM": "Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994 Oct-Nov;30(3):187-228. PMID: 7862618", "BibTeX": "@article{7862618, title={Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.}, author={Sirtori CR and Pasik C}, journal={Pharmacol Res}, volume={30}, number={3}, pages={187-228}}"}}]}